Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by her2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28:92.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1979;1987(235):182–91.

Google Scholar 

Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320–68.

Article  CAS  PubMed  Google Scholar 

McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002;62:209–43. https://doi.org/10.2165/00003495-200262010-00008. (cited 23 Jan 2023).

Article  CAS  PubMed  Google Scholar 

Jackisch C, Schoenegg W, Reichert D, Welslau M, Selbach J, Harich H-D, et al. Trastuzumab in advanced breast cancer—a decade of experience in Germany. BMC Cancer. 2014;14:924.

Article  PubMed  PubMed Central  Google Scholar 

De Mattos-Arruda L, Cortes J, De M-A, Cortes J. Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist. 2012;17:631–44.

Article  PubMed  PubMed Central  Google Scholar 

Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, et al. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer—a systematic review. Breast Cancer Res. 2015;17:140.

Article  PubMed  PubMed Central  Google Scholar 

Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24:2786–92.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

Article  CAS  PubMed  Google Scholar 

Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–74.

Article  CAS  PubMed  Google Scholar 

Ahmed S, Sami A, Xiang J. HER2-directed therapy: current treatment options for HER2-positive breast cancer. Breast Cancer. 2015;22:101–16.

Article  PubMed  Google Scholar 

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, et al. 3rd ESO-ESMO International Consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. 2017;28:16–33 (cited 23 Jan 2023).

Article  CAS  PubMed  Google Scholar 

Michael YLD, Kawachi I, Berkman LF, Holmes MD, Colditz GA, Corsano K, et al. The persistent impact of breast carcinoma on functional health status: prospective evidence from the Nurses’ Health Study. Cancer. 2000;89(11):2176–86.

Article  CAS  PubMed  Google Scholar 

Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. Cancer. 2008;112:2577–92.

Article  PubMed  Google Scholar 

Snyder CF, Aaronson NK. Use of patient-reported outcomes in clinical practice. Lancet. 2009;374:369–70.

Article  PubMed  Google Scholar 

Marshall S, Haywood K, Fitzpatrick R. Impact of patient-reported outcome measures on routine practice: a structured review. J Eval Clin Pract. 2006;12:559–68.

Article  PubMed  Google Scholar 

Frank L, Basch E, Selby JV. The PCORI perspective on patient-centered outcomes research. JAMA. 2014;312:1513–4.

Article  CAS  PubMed  Google Scholar 

Riis CL, Bechmann T, Jensen PT, Coulter A, Steffensen KD, Lundgaard Riis C, et al. Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review. Patient Relat Outcome Meas. 2019;10:117–27.

Article  PubMed  PubMed Central  Google Scholar 

Stefanovic S, Wallwiener M, Karic U, Domschke C, Katic L, Taran FA, et al. Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications. Support Care Cancer. 2017;25:549–58.

Article  PubMed  Google Scholar 

Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J, et al. Global analysis of advanced/metastatic breast cancer: decade report (2005–2015). Breast. 2018;39:131–8.

Article  PubMed  Google Scholar 

Rautalin M, Färkkilä N, Sintonen H, Saarto T, Taari K, Jahkola T, et al. Health-related quality of life in different states of breast cancer—comparing different instruments. Acta Oncol. 2018;57:622–8.

Article  PubMed  Google Scholar 

Hamer J, McDonald R, Zhang L, Verma S, Leahey A, Ecclestone C, et al. Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer. 2017;25:409–19.

Article  PubMed  Google Scholar 

El Fakir S, El Rhazi K, Zidouh A, Bennani M, Benider A, Errihani H, et al. Health-related quality of life among breast cancer patients and influencing factors in Morocco. Asian Pac J Cancer Prev. 2016;17:5063.

PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178–89 (cited 7 Dec 2023).

Article  PubMed  Google Scholar 

Ilic L, Haidinger G, Simon J, Hackl M, Schernhammer E, Papantoniou K. Trends in female breast cancer incidence, mortality, and survival in Austria, with focus on age, stage, and birth cohorts (1983–2017). Sci Rep. 2022;12. Available at: https://www.nature.com/articles/s41598-022-10560-x. [cited 9 Dec 2023].

Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004;57:898–910.

Article  PubMed  Google Scholar 

Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 2016;16:139–44.

Article  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:I4898. Available at: https://www.bmj.com/content/366/bmj.l4898. [cited 19 Feb 2023].

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:I4919. Available at: https://www.bmj.com/content/355/bmj.i4919. [cited 19 Feb 2023]

Perez EA, Barrios C, Eiermann W, Toi M, Im Y-H, Conte P, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35:141–8.

Article  CAS  PubMed  Google Scholar 

Wu Y, Amonkar MM, Sherrill BH, O’Shaughnessy J, Ellis C, Baselga J, et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2011;22:2582–90.

Article  CAS  PubMed  Google Scholar 

Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor–positive metastatic breast cancer: updated results of alternative. J Clin Oncol. 2021;39:79–89.

Article  CAS  PubMed  Google Scholar 

Rugo H, Brammer M, Zhang F, Lalla D. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer. 2010;10:288–93.

Article  CAS  PubMed  Google Scholar 

Schwartzberg L, McIntyre K, Wilks S, Puhalla S, O’Shaughnessy J, Berrak E, et al. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer. BMC Cancer. 2019;19:578 (cited 25 May 2022).

Article  PubMed  PubMed Central  Google Scholar 

Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31:1157–63.

Article  CAS  PubMed  Google Scholar 

Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol. 2002;20:3106–13.

Article  CAS  PubMed  Google Scholar 

Syrios J, Pappa E, Volakakis N, Grivas A, Alafis J, Manioudaki S, et al. Real-world data on health-related quality of life assessment in patients with breast cancer receiving subcutaneous trastuzumab. Breast Cancer (Auckl). 2018;12:1178223418758031 (cited 12 Sep 2021).

PubMed  PubMed Central  Google Scholar 

Wöckel A, Schwentner L, Krockenberger M, Kreienberg R, Janni W, Wischnewsky M, et al. Predictors of the course of quality of life during therapy in women with primary breast cancer. Qual Life Res. 2017;26:2201–8.

Article  PubMed  Google Scholar 

Hsu HT, Lin KC, Wu LM, Juan CH, Hou MF, Hwang SL, et al. Symptom cluster trajectories during chemotherapy in breast cancer outpatients. J Pain Symptom Manag. 2017;53:1017–25.

Article